In common with other plasma cell dyscrasias in which a small tumour burden is associated with severe clinical symptoms (notably systemic AL amyloidosis) the possible benefits of dose intensification are yet to be fully explored in POEMS syndrome. One important issue is whether the toxicity of the procedure is significantly increased in this group. We report two The acronym POEMS aids recognition of the more common features of a rare multi-system disorder associated with an underlying plasma cell dyscrasia (polyneuropathy, organomegaly (hepatosplenomegaly, lymphadenopathy), endocrinopathy (diabetes mellitus, hypogonadism, hypothyroidism), monoclonal gammopathy and skin changes (most frequently hyperpigmentation)).
The acronym POEMS aids recognition of the more common features of a rare multi-system disorder associated with an underlying plasma cell dyscrasia (polyneuropathy, organomegaly (hepatosplenomegaly, lymphadenopathy), endocrinopathy (diabetes mellitus, hypogonadism, hypothyroidism), monoclonal gammopathy and skin changes (most frequently hyperpigmentation)). 1, 2 In only a minority of cases are all the criteria met. A constellation of other clinical manifestations may be present including peripheral oedema, ascites, pleural effusions, pulmonary hypertension, papilloedema, polycythaemia, thrombocytosis and fever. 3 Bone lesions are also common. Miralles et al 4 described 38 patients, of whom 36 had bone lesions. In 31 of these the lesions were sclerotic or mixed sclerotic/lytic rather than predominantly lytic. The pathophysiological basis of the polyneuropathy along with other features of the disorder remains unclear. There is only limited evidence to support a direct role of the monoclonal protein in the neuropathy, 5 but it remains apparent that a small tumour burden may be associated with severe clinical symptoms. High-dose therapy combined with stem cell support offers potential benefits, but these must be balanced against the possibility of increased toxicity as in systemic amyloidosis. We report two cases of POEMS syndrome treated with high-dose melphalan and PBSC rescue.
Case reports

Case 1
A 56-year-old Caucasian male presented with distal lower limb paraesthesia progressing proximally with subsequent development of a similar pattern of lower limb weakness and then upper limb involvement. Within 3 months he was unable to walk or stand. There were no cranial nerve symptoms and no sphincter dysfunction. He began to develop impotence at the time of onset of his first neurological symptoms but no other features suggestive of autonomic neuropathy. His mild longstanding psoriatic nail changes progressed markedly coincident with the neurological symptoms. In addition, his previously well-controlled noninsulin-dependent diabetes mellitus deteriorated requiring insulin to maintain glycaemic control. Clinical examination revealed a marked symmetrical peripheral sensorimotor polyneuropathy, more pronounced distally and in the lower limbs. Examination of the cranial nerves was normal. Neurophysiological testing showed a severe demyelinating neuropathy with significant secondary axonal loss. The cerebrospinal fluid protein level was raised (2 g/l) but there was no pleiocytosis. Significant normal or negative results included full blood count, renal and hepatic function tests, magnetic resonance imaging (MRI) of the brain, cervical and lumbar spine, auto-antibody screen, complement levels, cryoglobulin screen, hepatitis/ Treponemal/Legionella/Campylobacter/Lyme disease serology, urinary porphyrin screen, haematinic (B12 and folate) levels and thyroid function tests. Blood glucose was raised (15.8 mmol/l, reference interval 3.3-9.0 mmol/l) and serum testosterone was reduced (6.8 nmol/l, reference interval 9-33 nmol/l), with a prolactin level at the upper end of the reference interval (389 mU/l, reference intervel 31.5-399 mU/l). Serum electrophoresis revealed a monoclonal IgG protein quantified at 1.1 g/l with minimally reduced IgM levels (0.3 g/l). There was no Bence-Jones proteinuria. Bone marrow aspirate and trephine biopsy were unremarkable. Abdominal ultrasound showed a mildly enlarged spleen (14.7 cm) but no hepatomegaly. Skeletal survey revealed a single mixed sclerotic and lytic lesion in the right humeral head (Figure 1 ), which demonstrated increased tracer uptake on a radionucleotide bone scan. There were no other areas of increased uptake. Biopsy of this lesion under CT guidance demonstrated a plasmacytoma with light chain restriction.
Initial treatment with intravenous immunoglobulin (IVIg) (0.4 g/kg/day for 5 days) and subsequent intravenous methylprednisolone (1 g/day for 3 days) failed to result in clinical benefit. Following confirmation that the humeral lesion was a plasmacytoma the patient received further IVIg (0.4 g/kg/day for 5 days) followed by radiotherapy to the lesion (23 Gy in seven fractions). The neuropathy continued to progress during treatment and the vital capacity fell from 4 to 2.1 litres. He therefore underwent peripheral blood stem cell harvesting following cyclophophamide priming (1.5 g/m 2 ). By this time the neuropathy had stabilised but the patient had completely lost the use of his lower limbs (maximal muscle strength Ϫ movement against gravity) and retained little functional use of his upper limbs due to loss of distal muscle strength. Because of concern regarding the possibility of a further fall in vital capacity the patient proceeded to receive high-dose melphalan (200 mg/m 2 ) with CD34-selected PBSC rescue. The CD34 + ve cell dose returned was 2.5 ϫ 10 6 /kg. The posttransplant course was uneventful other than the development of a tender peri-anal lesion and febrile neutropenia that settled with broad-spectrum antibacterial therapy. Neutrophil engraftment (Ͼ0.5 ϫ 10 9 /l) occurred on day +11 and platelet engraftment (Ͼ50 ϫ 10 9 /l) on day +19. Initial improvement in strength was noted within 2 weeks following high-dose treatment. By 6 months post transplant there was marked improvement in strength, physical and self-care skills. He was able to walk unaided and climb stairs. Balance remained impaired due to reduced proprioception. Return of upper limb function occurred more slowly. Occupational therapy aids allowed him to become essentially independent in personal care. There was near resolution of the dystrophic nail changes, but the patient remained dependent on insulin for glycaemic control. The patient is well with gradual improvement in the peripheral neuropathy 2 years following PBSCT. The paraprotein remains too small to quantitate.
Case 2
A 38-year-old female initially presented with headache and lethargy and was diagnosed as having benign intracranial hypertension. She was treated with diuretics and repeated lumbar punctures but re-presented 7 months later with amenorrhoea, dry skin, poor concentration and weight loss. Clinical examination revealed cachexia, hepatosplenomegaly, gross peripheral oedema with no evidence of cardiac failure, scleroderma-like skin changes and peripheral neuropathy. Further investigations confirmed a diagnosis of hypothyroidism and hypoadrenalism with elevated thyroid microsomal antibodies and normal anterior pituitary function. A CT scan revealed 20 cm splenomegaly, hepatomegaly and ascites. A liver biopsy did not show any evidence of cirrhosis. MRI of the brain was normal. An IgA paraprotein was detected on immunofixation along with monoclonal urinary light chains. Serum vitamin B12 level was low in the absence of parietal cell or intrinsic factor antibodies. Bone marrow aspirate and trephine biopsy were unremarkable with a normal karyotype. Fat aspiration and SAP scan showed no evidence of amyloid deposition. Skeletal survey showed a single sclerotic lesion in the pelvis. Nerve conduction studies were consistent with a predominantly demyelinating motor peripheral neuropathy.
A diagnosis of POEMS syndrome was made and she received three cycles of VAMP chemotherapy. Although there was some overall symptomatic improvement, it was complicated by worsening neuropathy possibly due to /kg. The post-transplant course was complicated by severe mucositis and febrile neutropenia that responded to broad-spectrum antibiotics. Neutrophil and platelet engraftment were on day +15 and day +19, respectively. By 6 months post transplant there was a reduction of the organomegaly (normal liver and 16 cm spleen on ultrasound) and resolution of ascites. There was no detectable serum paraprotein or urinary monoclonal light chains on immunofixation. Nerve conduction studies revealed a persistent predominantly demyelinating motor peripheral neuropathy. There were no significant improvements in the endocrinopathies. The sclerotic lesion in her pelvis is due to be irradiated.
Discussion
The association between monoclonal gammopathy and peripheral neuropathy has long been recognised. Up to 10% of patients with idiopathic polyneuropathies are reported to have a monoclonal protein demonstrable in the serum and/or urine, 6 representing a prevalence of 6-10 times that in the general population. Conversely, the prevalence of peripheral neuropathy in patients presenting with monoclonal gammopathy of uncertain significance has been reported to vary widely according to the diagnostic criteria used. The association appears to be more common in patients with an IgM (15%), rather than either an IgA (7%) or IgG (3%) paraprotein. 7 A causal role for the paraprotein in the development of neuropathy has been difficult to prove, even in the cases with the best-documented associations (the demyelinating neuropathies associated with IgM anti-myelin-associated glycoprotein (MAG) antibody and anti-ganglioside antibodies). It has been argued that the antibodies in these cases may represent a secondary rather than a primary phenomenon, particularly as there appears to be no direct correlation between the severity of the neuropathy and the level of M-protein or its affinity for neural antigen in some studies. 8 A causal role is more obvious in those cases resulting from the deposition of monoclonal protein in the form of amyloid resulting in axonal degeneration involving unmyelinated and lightly myelinated fibres. 9 Symmetrical proximally advancing sensory and subsequent motor neuropathy combined with evidence of both demyelination and (probably secondary) axonal degeneration is a central feature of POEMS syndrome. 8 In the majority of patients the polyneuropathy follows a slowly progressive course over a number of years in the absence of treatment. The pathophysiological basis for the systemic manifestations of the syndrome is unclear. Unlike the neuropathies associated with anti-neuronal IgM antibodies in which immunoglobulin deposition can be demonstrated on nerve biopsies, the neuropathy associated with POEMS syndrome has only rarely been associated with immunoglobulin deposits. 10 More recently, alternative possible mediators of the characteristic syndromic features including IL-6, TNF␣, VEGF and IL-1␤ have been documented. The unusually aggressive nature of the neurological damage in case 1 prompted the relatively early use of high-dose chemotherapy and stem cell rescue. The relative contributions of the radiotherapy and subsequent chemotherapy to the overall clinical improvement in this case remain uncertain. Since the disorder is relatively rare much of the published literature on treatment takes the form of case studies. While both plasmapheresis and IVIg infusions have been used with some success in patients with myelin-specific antibodies, most reported cases of POEMS syndrome have been resistant to these forms of therapy. 11 Results with IVIg have been mixed, 12, 13 and often the contribution of the IVIg to any documented improvement has been difficult to assess in view of the use of additional treatment modalities such as radiotherapy. The precise mode of action of IVIg also remains unclear but it may work in part by blocking the Fc receptors of immune effector cells. If the pathological basis of the neuropathy in POEMS syndrome is not directly related to the monoclonal protein this form of therapy might be predicted to be ineffective.
Treatment of cases of POEMS syndrome with solitary bone lesions by surgery, radiotherapy or both, usually results in improvement in the neuropathy, suggesting that a soluble factor elaborated by the plasmacytoma or alternative cells in the same vicinity may be responsible for the extramedullary manifestations. Systemic chemotherapy has been used in cases with multiple disseminated bony lesions. This has generally taken the form of melphalan and prednisolone.
14 As in the case of other plasma cell dyscrasias, relapse (in this setting associated with progression of neurological and other systemic features) may occur after many years of apparent cure. High-dose therapy with PBSC rescue has become a part of routine therapy for myeloma in many centres. Its role in the management of other plasma cell dyscrasias in which a small tumour burden is associated with severe clinical symptoms (notably systemic AL amyloidosis) is yet to be fully defined. 15 Since the majority of patients with POEMS has a more slowly progressive disorder which often responds to less aggressive therapy its role in the treatment of this disorder may be even harder to define. Cases associated with a single bone lesion may be considered for local therapy in the first instance. The published data on solitary plasmacytoma of bone suggests a disease-free survival of over 40% at 5 years and median overall survival of over 10 years for similar lesions outside the setting of POEMS syndrome. 16 Significantly, however, the persistence of a relatively small tumour mass in these cases is generally not associated with substantial morbidity. Experience with systemic amyloidosis demonstrates that application of PBSCT may be associated with increased morbidity and mortality in the setting of pre-existing multisystem pathology. 15 The two cases in this report show that PBSCT can be performed without excessive toxicity in POEMS syndrome, adding to the recent experience reported as a case study from the Mayo Clinic, 17 and five cases reported by Jaccard et al 18 including two undergoing tandem transplant procedures. In the latter study there were no procedure-related mortalities and morbidity appeared no higher than for patients with classic multiple myeloma. A further four cases conditioned with melphalan 200 mg/m 2 were reported from the Mayo Clinic in abstract form. 19 Two had a relatively uncomplicated course, one had significant infective complications resulting in mechanical ventilation, and one died as a result of complications of graft failure. Thus the collective experience reported to date suggests that PBSCT can be performed in patients with POEMS syndrome without the increased morbidity associated with amyloidosis. However, the disorder is rare and the combined experience remains relatively small. PBSCT is undoubtedly associated with some morbidity and mortality and in cases associated with solitary lesions alternative less toxic approaches such as local radiotherapy may be more appropriate. All of the cases reported to date have proceeded to PBSCT either because of severe and rapidly progressive neuropathy or because of multifocal bone lesions and/or diffuse plasmacytic bone marrow infiltration. In view of the relatively young age of patients with POEMS syndrome high-dose therapy should be considered among the available treatment options, at least for those cases with multiple bony lesions or severe and rapidly progressive neurological deterioration. At present, there is no evidence to suggest that incorporation of total body irradiation into the conditioning therapy is beneficial.
